Insilico has initiated Phase III trials of Rentosertib, an oral TNIK inhibitor designed through AI-driven drug discovery, for idiopathic pulmonary fibrosis. The 52-week trial enrolling 320 patients will measure the drug's capacity to slow lung function decline, a primary determinant of IPF progression and mortality risk.
Key Points
- Phase III trial enrolls 320 IPF patients across 47 Chinese centers
- AI-designed TNIK inhibitor showed +98.4mL FVC improvement in Phase IIa
- Primary endpoint measures annual rate of forced vital capacity decline
Longevity Analysis
Idiopathic pulmonary fibrosis represents a progressive failure of gas exchange and tissue regeneration with median survival of 3-5 years post-diagnosis. A mechanistic intervention targeting TNIK signaling addresses the fibrotic cascade itself rather than symptomatic management alone. Success in this trial would establish a disease-modifying approach for a condition currently managed primarily through supportive care and transplant consideration, directly extending both healthspan and lifespan in affected populations.
Original published by Longevity.Technology.